Michael Andersson
About
Michael Andersson is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Michael Andersson has authored 123 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 39 papers in Cancer Research and 24 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Michael Andersson's work include Breast Cancer Treatment Studies (34 papers), Cancer Treatment and Pharmacology (31 papers) and HER2/EGFR in Cancer Research (30 papers). Michael Andersson is often cited by papers focused on Breast Cancer Treatment Studies (34 papers), Cancer Treatment and Pharmacology (31 papers) and HER2/EGFR in Cancer Research (30 papers). Michael Andersson collaborates with scholars based in Denmark, Sweden and United States. Michael Andersson's co-authors include Hans H. Storm, Eero Pukkala, Lois B. Travis, Charles F. Lynch, Eric J. Holowaty, Mary Gospodarowicz, Maj‐Britt Jensen, Claus Kamby, Per Hall and Henning T. Mouridsen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.
In The Last Decade
Michael Andersson
121 papers receiving 7.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Michael Andersson Denmark | 37 | 3.2k | 2.2k | 1.7k | 1.7k | 1.6k | 123 | 7.6k | ||
| Graça M. Dores United States | 31 | 2.9k 0.9× | 1.2k 0.5× | 1.9k 1.1× | 1.9k 1.2× | 1.7k 1.0× | 83 | 8.1k | ||
| Vittorina Zagonel Italy | 52 | 5.3k 1.6× | 1.4k 0.7× | 2.4k 1.4× | 1.4k 0.9× | 3.0k 1.8× | 467 | 11.4k | ||
| Carien L. Creutzberg Netherlands | 61 | 2.9k 0.9× | 1.9k 0.8× | 1.7k 1.0× | 2.3k 1.3× | 1.5k 0.9× | 208 | 15.5k | ||
| Gabe S. Sonke Netherlands | 42 | 4.2k 1.3× | 2.3k 1.0× | 1.7k 1.0× | 2.0k 1.2× | 925 0.6× | 314 | 8.2k | ||
| Michael Schaapveld Netherlands | 37 | 2.2k 0.7× | 1.1k 0.5× | 1.2k 0.7× | 1.2k 0.7× | 1.4k 0.8× | 155 | 5.7k | ||
| George Pentheroudakis Greece | 43 | 4.5k 1.4× | 1.3k 0.6× | 1.5k 0.9× | 983 0.6× | 1.7k 1.0× | 228 | 7.6k | ||
| Xuemei Wang United States | 54 | 2.8k 0.9× | 1.0k 0.5× | 3.1k 1.8× | 1.8k 1.1× | 1.4k 0.9× | 252 | 10.4k | ||
| Alan Horwich United Kingdom | 45 | 2.6k 0.8× | 1.5k 0.7× | 5.6k 3.2× | 2.4k 1.5× | 1.8k 1.1× | 140 | 10.4k | ||
| Bernard Asselain France | 59 | 5.2k 1.6× | 4.4k 2.0× | 2.1k 1.2× | 1.8k 1.1× | 2.6k 1.6× | 323 | 11.0k | ||
| Hemming Johansson Sweden | 44 | 4.4k 1.4× | 1.7k 0.7× | 1.2k 0.7× | 2.3k 1.4× | 809 0.5× | 186 | 7.6k |
Countries citing papers authored by Michael Andersson
Since
Specialization
Citations
This map shows the geographic impact of Michael Andersson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Andersson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Andersson more than expected).
Fields of papers citing papers by Michael Andersson
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael Andersson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Andersson. The network helps show where Michael Andersson may publish in the future.
Co-authorship network of co-authors of Michael Andersson
This figure shows the co-authorship network connecting the top 25 collaborators of Michael Andersson. A scholar is included among the top collaborators of Michael Andersson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Andersson. Michael Andersson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Berg, Tobias, et al.. (2023). Real-world survival of Danish patients with HER2-positive metastatic breast cancer. Acta Oncologica. 62(6). 601–607.
2.
Pedersen, Julie Elbæk, Katrine Strandberg‐Larsen, Michael Andersson, & Johnni Hansen. (2021). Occupational exposure to solar ultraviolet B radiation and risk of subtypes of breast cancer in Danish women. Occupational and Environmental Medicine. 78(4). 286–292.
3.
Pedersen, Julie Elbæk, Katrine Strandberg‐Larsen, Michael Andersson, & Johnni Hansen. (2020). Occupational exposure to specific organic solvents and risk of subtypes of breast cancer in a large population of Danish women, 1964–2016. Occupational and Environmental Medicine. 78(3). 192–198.
4.
Berg, Tobias, et al.. (2020). Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG). The Breast. 54. 242–247.
5.
Andersson, Linda, et al.. (2018). Medical Entity Corpus with PICO elements and Sentiment Analysis. Language Resources and Evaluation.
6.
Lindman, Henrik, Michael Andersson, Johan Ahlgren, et al.. (2018). A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1). European Journal of Cancer. 94. 79–86.
7.
Mertz, Birgitte Goldschmidt, Niels Kroman, Christoffer Johansen, et al.. (2017). The effects of individually tailored nurse navigation for patients with newly diagnosed breast cancer: a randomized pilot study. Acta Oncologica. 56(12). 1682–1689.
8.
Sonnenblick, Amir, Dominique Agbor‐Tarh, Ian Bradbury, et al.. (2017). Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. Journal of Clinical Oncology. 35(13). 1421–1429.
9.
Perez, Edith A., José Manuel López-Vega, Thierry Petit, et al.. (2016). Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Research. 18(1). 126–126.
10.
Kjær, Susanne K., et al.. (2015). Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort study. Breast Cancer. 23(6). 908–916.
11.
Nielsen, Dorte, Iben Kümler, Jesper Andreas Palshof, & Michael Andersson. (2012). Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. The Breast. 22(1). 1–12.
12.
Minckwitz, Gϋnter von, Kathrin Schwedler, Marcus Schmidt, et al.. (2011). Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer. 47(15). 2273–2281.
13.
Jensen, Jeanette Dupont, Ann Knoop, Anne‐Vibeke Lænkholm, et al.. (2011). PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Annals of Oncology. 23(8). 2034–2042.
14.
Rosendahl, Mikkel, Johan Ahlgren, Jørn Andersen, et al.. (2009). The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000-1 study. European Journal of Cancer. 45(18). 3198–3204.
15.
Nielsen, Dorte, Michael Andersson, & Claus Kamby. (2008). HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treatment Reviews. 35(2). 121–136.
16.
Andersson, Michael, Dorthe Susanne Nielsen, Peter G. Sørensen, & Marianne Ewertz. (2007). Phase II trial of vinorelbine (V) days 1+8 every 3 weeks and trastuzumab (T) weekly as first-line chemotherapy for HER2+ metastatic breast cancer (MBC). Journal of Clinical Oncology. 25(18_suppl). 1091–1091.
17.
Travis, Lois B., Sophie D. Fosså, Sara J. Schonfeld, et al.. (2005). Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors. JNCI Journal of the National Cancer Institute. 97(18). 1354–1365.
18.
Travis, Lois B., Deirdre A. Hill, Graça M. Dores, et al.. (2003). Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease. JAMA. 290(4). 465–465.
19.
Travis, Lois B., Michael Hauptmann, Linda Gaul, et al.. (2003). Site-Specific Cancer Incidence and Mortality after Cerebral Angiography with Radioactive Thorotrast. Radiation Research. 160(6). 691–706.
20.
Overgaard, Marie, Maj‐Britt Jensen, Jens Overgaard, et al.. (1999). Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. The Lancet. 353(9165). 1641–1648.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Graça M. Dores Breakdown of academic impact, for papers by Vittorina Zagonel Breakdown of academic impact, for papers by Carien L. Creutzberg Breakdown of academic impact, for papers by Gabe S. Sonke Breakdown of academic impact, for papers by Michael Schaapveld Breakdown of academic impact, for papers by George Pentheroudakis Breakdown of academic impact, for papers by Xuemei Wang Breakdown of academic impact, for papers by Alan Horwich Breakdown of academic impact, for papers by Bernard Asselain Breakdown of academic impact, for papers by Hemming Johansson